The Meilahti Tower Hospital, part of the Helsinki University Central Hospital, is the largest hospital in Finland, located in the Meilahti district of Helsinki. The hospital has a helipad with the ICAO airport code EFHY.

There are 538 beds in HUS, Meilahden sairaala.

During the past decade, HUS, Meilahden sairaala conducted 12 clinical trials. In the 10-year time frame, 12 clinical trials started and 2 clinical trials were completed, i.e. on average, 16.7% percent of trials that started reached the finish line to date. In the past 5 years, 6 clinical trials started and 2 clinical trials were completed. i.e. 33.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "HUS, Meilahden sairaala" #1 sponsor was "Bayer" with 8 trials, followed by "Helsinki University Central Hospital" with 5 trials sponsored, "Anna Martling" with 1 trials sponsored, "Boston Scientific Corporation" with 1 trials sponsored and "RhoVac APS" with 1 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "HUS, Meilahden sairaala" #1 collaborator was "Population Health Research Institute" with 1 trials as a collaborator, "Skane University Hospital" with 1 trials as a collaborator and "Uppsala University Hospital" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "HUS, Meilahden sairaala" are "Appendicitis" (2 trials), "Abdominal Abscess" (1 trials), "Acute Non-cardioembolic Ischemic Stroke" (1 trials), "Acute Respiratory Distress Syndrome" (1 trials) and "Advanced Pancreatic Ductal Adenocarcinoma (Optional, Dose Expansion, Not Initiated)" (1 trials). Many other conditions were trialed in "HUS, Meilahden sairaala" in a lesser frequency.

Most popular intervention types in "HUS, Meilahden sairaala" are "Drug" (11 trials), "Other" (5 trials), "Device" (2 trials), "Biological" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (3 trials), "9% Sodium Chloride solution for injection" (1 trials), "Acetylsalicylic acid" (1 trials), "Apixaban" (1 trials) and "Apixaban matching placebo" (1 trials). Other intervention names were less common.

The vast majority of trials in "HUS, Meilahden sairaala" are 12 trials for "All" genders and 4 trials for "Male" genders.

Currently, there are NaN active trials in "HUS, Meilahden sairaala". undefined are not yet recruiting, 4 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 8 completed trials in HUS, Meilahden sairaala, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in HUS, Meilahden sairaala, 3 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 4 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 1 trials that are defined as “Not Applicable".